Gene therapy for inflammatory conditions
OwnerJan E. Brinchmann, Tommy A. Karlsen +1inventors
InventorsJan E. Brinchmann, Tommy A. Karlsen, Rua Nader Al-Modawi
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of oligonucleotides to treat inflammatory diseases, and in particular to treat osteoarthritis and rheumatoid arthritis. The oligonucleotides preferably comprise the seed sequence 5′-CCACAGG-3′ (SEQ ID NO: 6) situated at positions 2 to 8 of the oligonucleotide.
Claims24
1-17. (canceled)
Oligonucleotide composition comprising one or more nucleotides, or salts thereof, wherein the one or more oligonucleotides is at least 80% identical to a sequence selected from the group consisting of SEQ ID NOs:1, 2 and 3 with the proviso that the oligonucleotides comprise the seed sequence CCACAGG (SEQ ID NO:6) situated at positions 2-8 from the 5′ end of the oligonucleotide.
(canceled)
(canceled)
A sterile pharmaceutical composition suitable for intra-articular administration comprising an oligonucleotide selected from the group consisting of SEQ ID NOs:1, 2 and 3, wherein the oligonucleotide is double-stranded and comprises at least one phosphorothioate linkage and at least one 2′-Fluoro or 2′-Methoxy base.
(canceled)
A method of treating an inflammatory disease in subject in need thereof comprising administering to the subject an oligonucleotide that is at least 80% identical to any one of SEQ ID NOs:1, 2 or 3 with the proviso that the oligonucleotides comprise the seed sequence CCACAGG (SEQ ID NO:6) situated at positions 2-8 from the 5′ end of the oligonucleotide.
Dependencies are inferred from the claim text.